Clinical Trials Browser

Mesothelioma, Malignant × Dermatologic × 90 days × Clear all

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT03420963 2026-03-03

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Phase 1 Terminated

12 enrolled

DermatologicGenitourinaryHead & NeckOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Bone Neoplasms, Endocrine Gland Neoplasms, Melanoma, Mouth Neoplasms, Pharyngeal Neoplasms, Sarcoma, Skin Neoplasms, Thyroid Neoplasms, Urologic Neoplasms

NCT07403630 2026-02-17

IT-TCP POS

Phase NA Recruiting

300 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmOther solid neoplasmPlasma cellThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Squamous Cell, Melanoma, Multiple Myeloma, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

IT-TCP POS